Literature DB >> 22156906

SOM230 in Cushing's disease complicated by poorly controlled diabetes mellitus.

C Fiorentino, C Motta, D T Wolosinska, S Monti, F Mori, V Toscano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22156906     DOI： 10.1007/BF03345407

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  4 in total

1.  The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

Authors:  Leo J Hofland; Joost van der Hoek; Richard Feelders; Maarten O van Aken; Peter M van Koetsveld; Marlijn Waaijers; Diana Sprij-Mooij; Christian Bruns; Gisbert Weckbecker; Wouter W de Herder; Albert Beckers; Steven W J Lamberts
Journal:  Eur J Endocrinol       Date:  2005-04       Impact factor: 6.664

2.  Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Authors:  M Boscaro; W H Ludlam; B Atkinson; J E Glusman; S Petersenn; M Reincke; P Snyder; A Tabarin; B M K Biller; J Findling; S Melmed; C H Darby; K Hu; Y Wang; P U Freda; A B Grossman; L A Frohman; J Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

Review 3.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Authors:  B M K Biller; A B Grossman; P M Stewart; S Melmed; X Bertagna; J Bertherat; M Buchfelder; A Colao; A R Hermus; L J Hofland; A Klibanski; A Lacroix; J R Lindsay; J Newell-Price; L K Nieman; S Petersenn; N Sonino; G K Stalla; B Swearingen; M L Vance; J A H Wass; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

4.  Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.

Authors:  B Ambrosi; D Bochicchio; C Fadin; P Colombo; G Faglia
Journal:  J Endocrinol Invest       Date:  1990-03       Impact factor: 4.256
  4 in total
  1 in total

Review 1.  Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.

Authors:  Laura Trementino; Marina Cardinaletti; Carolina Concettoni; Giorgia Marcelli; Marco Boscaro; Giorgio Arnaldi
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.